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Background: Research has demonstrated that short meditation training may yield
higher pain tolerance in acute experimental pain. Our study aimed at examining
underlying mechanisms of this alleged effect. In addition, placebo research has shown
that higher pain tolerance is mediated via endogenous neuromodulators: experimental
inhibition of opioid receptors by naloxone antagonized this effect. We performed a
trial to discern possible placebo from meditation-specific effects on pain tolerance and
attention.
Objectives: It was proposed that (i) meditation training will increase pain tolerance; (ii)
naloxone will inhibit this effect; (iii) increased pain tolerance will correlate with improved
attention performance and mindfulness.
Methods: Randomized-controlled, partly blinded trial with 31 healthy meditation-naïve
adults. Pain tolerance was assessed by the tourniquet test, attention performance was
measured by Attention Network Test (ANT), self-perceived mindfulness by Freiburg
Mindfulness Inventory. 16 participants received a 5-day meditation training, focusing
on body/breath awareness; the control group (N = 15) received no intervention.
Measures were taken before the intervention and on 3 consecutive days after the
training, with all participants receiving either no infusion, naloxone infusion, or saline
infusion (blinded). Blood samples were taken in order to determine serum morphine
and morphine glucuronide levels by applying liquid chromatography-tandem mass
spectrometry analysis.
Results: The meditation group produced fewer errors in ANT. Paradoxically, increases
in pain tolerance occurred in both groups (accentuated in control), and correlated
with reported mindfulness. Naloxone showed a trend to decrease pain tolerance in
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both groups. Plasma analyses revealed sporadic morphine and/or morphine metabolite
findings with no discernable pattern.
Discussion: Main objectives could not be verified. Since underlying study goals
had not been made explicit to participants, on purpose (framing effects toward a
hypothesized mindfulness-pain tolerance correlation were thus avoided, trainees had
not been instructed how to ‘use’ mindfulness, regarding pain), the question remains
open whether lack of meditation effects on pain tolerance was due to these intended
‘non-placebo’ conditions, cultural effects, or other confounders, or on an unsuitable
paradigm.
Conclusion: Higher pain tolerance through meditation could not be confirmed.
Keywords: meditation, mindfulness, pain tolerance, attention, morphine, opioids, placebo
INTRODUCTION
Pain as an unpleasant sensory and emotional experience has
a multidimensional nature, which means it is sensitive to
diverse manipulations, implicating there are many starting
points for pain relief. Keeping in mind that, for example,
chronic pain patients cost about 38 billion Euros per year in
Germany (Zimmermann, 2004), reliable therapeutic concepts are
desperately needed. A better understanding of the notion of pain
is mandatory.
Pain Manipulation through Mindfulness
and Meditation
When observing the phenomenon of pain it appears that there
are several dimensions involved, from which the affective and
cognitive dimension are two: the affective dimension reflecting
the emotional and motivational relevance of the stimuli and the
cognitive dimension relating to how aspects of cognition can
sculpt one’s experience (Melzack and Casey, 1968). It seems quite
logical that manipulation on these two dimensions would lead to
an altered pain experience. Meditation, understood as a mental
training that shapes the brain/mind in highly specific ways, is a
relatively new approach in the field of pain modulation (Benson
et al., 1974; Hoffman et al., 1982; Kabat-Zinn, 1982, 2003; Kabat-
Zinn et al., 1985; Lazar et al., 2000; Esch et al., 2003; Salamon et al.,
2006; Zeidan et al., 2010, 2011, 2012; Schmidt et al., 2011) and
could be one of such starting points among others to manipulate
the affective and cognitive dimensions of pain.
Meditation lies at the core of mindfulness-based stress
reduction (MBSR). MBSR, since its development for chronic
pain and stress-associated disorders in the late 1970s, is under
intensive research (Kabat-Zinn, 1982; Kabat-Zinn et al., 1985;
Bishop et al., 2004; Grossman et al., 2004; Ernst et al., 2009;
Zeidan et al., 2010, 2011, 2012; cf. Bazarko et al., 2013;
Katterman et al., 2014), and now frequently used in clinical
practice. Evidence, however, for the clinical effectiveness of
MBSR programs in improving pain intensity or disability, e.g., in
chronic low back pain patients, is still inconclusive, with limited
evidence that MBSR can improve pain acceptance (Cramer et al.,
2012). A recent randomized clinical trial by Cherkin et al. (2016)
concluded that MBSR may be an effective treatment option for
patients with chronic low back pain, though effects were similar
to those of cognitive behavioral approaches, leaving the question
open as to the specificity of effects in mindfulness training. Kabat-
Zinn (2003, p. 145) defines mindfulness as “the awareness that
emerges through paying attention on purpose, in the present
moment, and non-judgmentally to the unfolding of experience
moment by moment.” Mindfulness has been suggested to be
effective via four mechanisms (Hölzel et al., 2011): attention
regulation, body awareness, emotion regulation, and changes in
perspective on the self.
This study was planned and conducted in light of recent
evidence demonstrating, indeed, that meditation alters pain
perception (e.g., reduction of subjective pain ratings in healthy
adults), and that pain tolerability for experimental pain is
elevated – since, for example, a short mindfulness training
has been shown to increase pain tolerance in novices (Kabat-
Zinn, 1982; Kabat-Zinn et al., 1985; Kingston et al., 2007;
Zeidan et al., 2010, 2011, 2012; MacCoon et al., 2012); however,
some of these early experimental studies on pain modulation
through meditation training didn’t involve proper controls or
randomization procedures. The postulated phenomenon has
recently been called ‘meditative analgesia’ by some authors
(Grant, 2014), also discussing various or ‘specific’ forms of
meditation that are particularly linked to the presumed potential
of affecting pain.
In addition, there is evidence for a modification of the
subjective interpretation of pain via meditation in patients
dealing with chronic pain (cf. Schmidt et al., 2011). However,
little is known about underlying neurobiological mechanisms.
For example, the involvement of dopamine or dopaminergic
brain pathways in meditation (Bujatti and Biederer, 1976; Kjaer
et al., 2002), and the production of endogenous opioids/opiates
via dopamine (Zhu et al., 2005; Kream and Stefano, 2006; Stefano
and Kream, 2007, 2010; Stefano et al., 2007, 2012; Mantione
et al., 2008; Zhu and Stefano, 2009; Esch, 2014), have been
discussed. An activation of these pathways could, theoretically,
influence pain modulation. Also, it has been speculated that pain
attenuation through mindfulness might involve unique brain
mechanisms that are in sharp contrast to established models, e.g.,
comprising increased sensory processing and decreased cognitive
control (Gard et al., 2011). Accordingly, a search for modulators
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and key neurotransmitters, or autoregulatory indicators, of this
proposed shift has begun.
Neurobiological Background and
Hypotheses Generation
In this regard, endogenous opioidergic (morphinergic) pathways
and agonistic signaling on mu3 and mu4 opioid receptors in
the brain received attention in meditation research, as well as a
coupling of related dopaminergic and nitric oxidergic pathways,
converging or originating in brain regions that critically process
pain (Bujatti and Biederer, 1976; Dusek et al., 2005; Mantione
et al., 2007; Jung et al., 2010; Hölzel et al., 2011; Kemper et al.,
2015). Part of the research background is that the potential of
endogenous production of morphine via dopamine has already
been shown, and related molecular pathways have been identified
(Zhu et al., 2005; cf. Kream and Stefano, 2006; Stefano and
Kream, 2007; Stefano et al., 2007, 2012; Mantione et al., 2008;
Zhu and Stefano, 2009); specific binding of morphine to the
mu (mu3/mu4) opioid receptor has been demonstrated (Guarna
et al., 2003; Cadet et al., 2004, 2007; Stefano et al., 2004, 2008a;
Zhu et al., 2004a; Mantione et al., 2006, 2010; Kream et al.,
2007; Welters et al., 2007; Fricchione et al., 2008; Ghelardini
et al., 2008; Zhu and Stefano, 2009; Pasternak and Pan, 2013).
In addition, morphine activates nitric oxide (NO)-producing
enzymes, and the activation of constitutive NO-synthases via
morphine has been demonstrated (Tseng et al., 2000; Welters
et al., 2000; Mantione et al., 2003, 2006, 2008; Stefano et al.,
2004, 2005, 2008b, 2009; Zhu et al., 2004a,b; Casares et al., 2005;
Pak et al., 2005; Cadet et al., 2007; Kream and Stefano, 2009,
2010; cf. Banach et al., 2010). In fact, coupling of constitutive
NO to cellular/physiological stress and pain reduction has
been discussed for long (cf. Esch et al., 2002). Finally, there
exists clear evidence for an elevation of pain tolerance via
opiate alkaloids (such as morphine) or opioid peptides – be
it externally administered or internally/endogenously activated
(e.g., Amanzio and Benedetti, 1999; Hutchinson et al., 2004;
Stefano et al., 2009; Bodnar, 2013; Hajj et al., 2013; Miguez
et al., 2014). Thus, we surmised that opioidergic/morphinergic
mechanisms might play a role in assumed meditation-related
alteration of pain tolerability.
Possible Placebo Analogies
Interestingly, quite similar mechanisms have already been
demonstrated for the placebo effect and related pain-associated
phenomena, and their physiology in this regard. This includes
evidence for the involvement of dopamine in placebo response
(de la Fuente-Fernández et al., 2001, 2006; Stefano et al.,
2005; Scott et al., 2008; de la Fuente-Fernández, 2009; Lidstone
et al., 2010), or an involvement of opioid transmission, i.e.,
opioid signaling mechanisms and/or receptors (Benedetti and
Amanzio, 1997; Amanzio and Benedetti, 1999; Benedetti et al.,
1999a,b, 2005, 2006; Amanzio et al., 2001; Ribeiro et al., 2005;
Zubieta et al., 2005; Scott et al., 2008; Schoell et al., 2010).
Furthermore, central mu opioid receptor (sub-) systems seem
to play a significant role in the placebo response, as do limbic
system (e.g., nucleus accumbens, anterior cingulate), prefrontal
(e.g., dorsolateral prefrontal cortex) and insular cortices (among
others: e.g., amygdala, periaqueductal gray matter), presumably
also via imbedded mu opioid receptor activation (cf. Ribeiro et al.,
2005; Zubieta et al., 2005).
Evidence exists for the involvement of the mu opioid
receptor system in placebo-analgesia (e.g., Ribeiro et al., 2005;
Zubieta et al., 2005; Schoell et al., 2010), and for an increment
(elevation) of pain tolerance by active elicitation of the placebo
response (e.g., Amanzio and Benedetti, 1999). Finally, the
opioid antagonist naloxone has been shown to reduce pain
tolerance in placebo studies on experimental pain tolerability
(e.g., Amanzio and Benedetti, 1999; Schoell et al., 2010), or
conditioning experiments (e.g., Flor et al., 2002), again showing
that effects are processed, at least partially, via the endogenous
opioidergic system. In fact, there is evidence that naloxone
selectively binds to mu opioid receptors, i.e., it particularly
antagonizes mu opiate signaling at least at lower or ‘physiological’
concentrations; some authors calculate naloxone affinity for the
mu receptor, as compared to delta or kappa opioid receptors,
with 20:1 (e.g., Zadina et al., 1993; Chong et al., 2006; Kim and
Richardson, 2009; Tsai et al., 2009; Jan et al., 2011). Importantly,
naloxone itself has no pain modifying effects, i.e., it does
not alter pain tolerance per se (Grevert and Goldstein, 1978;
Amanzio and Benedetti, 1999). Given this, the reduction of pain
tolerance following naloxone administration in placebo studies
(incorporating experimental pain models), as demonstrated, may
be linked to opioidergic, that is: morphinergic, mu receptor
signaling.
Study Objectives
On the basis of these considerations, we decided to study
the neurobiological aspects of pain modulation through
mindfulness-based meditation techniques in healthy participants.
We expected an increased pain tolerance in the meditation
training group. Comparable to the placebo effect, we speculated
that pain modulation is mediated via endogenous, opioidergic
mechanisms. Related opioid/opiate compounds (e.g., morphine
and its metabolites) should therefore be found in the plasma
of blood samples of the study participants, and also be blocked
by administration of opioid antagonists, such as naloxone. This
effect would imply an involvement of the mu opioid receptor,
which is particularly sensitive to naloxone and which has – with
its subtypes mu3 and mu4 – a high affinity to the opiate alkaloid
morphine.
Hence, the hypotheses (objectives) of our study were as
follows:
(A) Meditation increases pain tolerance in healthy adults (pre
meditation training compared to post, and intervention
group compared to non-meditating control group);
(B1) Effects of meditation on pain modulation/perception
are mediated via opioid mechanisms and can therefore
be blocked by administration of the opioid antagonist
naloxone;
(B2) Endogenous morphine is involved in meditation-
dependent pain modulation and can therefore be detected
in the plasma of study participants (blood collected pre
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and post; plasma analyzed by liquid chromatography-
tandem mass spectrometry for morphine and morphine
glucuronides – M3G, M6G);
(C) Increased pain tolerance following meditation training (see
A) correlates with improved attention performance [as
measured by the Attention Network Test (ANT)], as well
as increased self-perceived mindfulness [assessed by the
Freiburg Mindfulness Inventory (FMI)].
MATERIALS AND METHODS
Design
This study was conducted as a randomized control trial (RCT).
Procedures were conducted in a partly blinded manner (see
below). The trial lasted 10 days with five measurement points.
Two assessments took place before the intervention (days 1 and
2) followed by the intervention taking place on five consecutive
days (days 3–7) and three assessments after the intervention (days
8–10).
Participants
The study sample consisted of participants who were recruited
via informative postings throughout university campus (Freiburg
University), as well as announcements on an internal digital
message board for employees. Participants had to be at
least 18 years old, language proficient, and without visual
impairment that would prevent them from completing the
research assessments. Excluded were those with any form of
addiction, regular use of pain medication, severe psychiatric
disease, epilepsy, diabetes, pregnancy or prior meditation
experience. Participation included five visits to the University
Medical Center for assessment lasting approximately 2 h (days
1, 2, 8–10) and for participants randomized to the invention
group five meditation sessions (1.5 h, days 3–7). Participation was
voluntary, and all participants received a compensation of 150 €;
for their participation. We calculated a sample size of ≥30 which
was in accordance with prior studies on that topic and relevant
standard protocols (cf. Benedetti et al., 1999a; Zeidan et al., 2010,
2011).
All participants gave written informed consent.
Intervention
The participants were randomized either to a passive control
condition (no intervention N = 15) or trained in a combined
breathing/mindfulness meditation technique (intervention
group N = 16) for five consecutive days – i.e., five daily group
sessions of 1.5 h each. The topic of pain (e.g., pain awareness or
pain perception) was intentionally and carefully avoided in this
course. Training took place every day from 11:30 am until 1:00
pm.
The trainer (TE) had 20 years of meditation experience, and
is a professional meditation/mindfulness teacher, and researcher
in the field. Each training session consisted of feedback rounds
and exchanges on personal experiences, followed by 20–25 min
of formal group mindfulness meditation practice (techniques
taught: body scan, attention to breath (ATB), attention to
senses (ATS), open awareness/attention to experience (ATE),
and walking meditation – with focused breath awareness as
a steady anchor), and a length of 40 min on the last day.
Another feedback round followed each daily meditation practice
before the session closed. Participants were also motivated
to add another short/informal meditation practice during the
day/evening, left to their personal preference and choice (e.g.,
“mini meditation” – only a few breaths a couple of times during
the day – or another maximum 10–20 min of formal practice).
This suggestion was meant to individually complement daily
group meditation sessions, echoing and possibly deepening the
training. However, this suggested additional practice was not
formally assessed.
Measures
Pain Tolerance
Pain tolerance was measured two times before and three
times after the training in each participant through ischemia
induction in the forearm following a standard protocol (Benedetti
et al., 1999a), referred to as tourniquet test. In their original
experiments (Amanzio and Benedetti, 1999) investigated the
mechanisms underlying the activation of endogenous opioids in
placebo analgesia by using the model of human experimental
ischemic arm pain. Different types of placebo analgesic responses
were evoked by means of expectation, conditioning, or a
combination of both.
In our experiments, following this experimental setup,
participants reclined on a bed and 10 ml of blood was drained
from their dominant forearm. Next they had to extend their non-
dominant arm vertically and an Esmarch bandage was placed.
The bandage was used to squeeze the blood out of the arm.
A sphygmomanometer cuff was placed around the upper arm and
inflated to a pressure of 300 mm Hg to keep the arm virtually
empty of arterial blood supply, and a stopwatch was started.
After this, the bandage was removed and the arm lowered on
the participant’s side. Then, the participant had to squeeze a hand
exerciser 12 times by pressing the exerciser for 2 s and then resting
for 2 s. The force necessary to bring the handles together was
6.5 kg. The ischemic pain induced by this procedure increased
over time. Participants were asked to tolerate the pain until they
get the impression of not being able to withstand it any longer.
Once the participant indicated that this point was reached the
stop-watch was stopped and the cuff was immediately deflated.
Three minutes after the end of the tourniquet test a second blood
sample of 10 ml was taken from the dominant forearm.
On two of the three post-intervention assessments on days
9 and 10, immediately before the pain tolerance measurements,
participants received a blinded infusion of either naloxone or
saline on either day 9 or day 10 in randomized sequence.
Following a blinded, randomized protocol the infusion was
administered by a perfusor via a venous port. Naloxone
concentration was 0.14 mg/kg in 0.9% NaCl-solution with
0.1 ml/s; the total infusion time was 180–250 s. The infusion port
was kept open until 8 ml of NaCl-solution passed. Study assistants
as well as participants were blinded to the content of the infusion.
As explanation for the i.v. line participants were told that a
neutral substance without any effect was administered, usually
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used for detoxification and now applied in this study to facilitate
the assessment of certain blood parameters. The procedures
followed a standard protocol (see Amanzio and Benedetti, 1999).
After day 10, all participants had received hidden naloxone and
saline, once in each case.
Morphine and Morphine Metabolites
Total morphine concentrations after enzymatic cleavage of
glucuronides and the concentrations of the morphine metabolites
morphine-3-glucoronide (M3G) and morphine-6-glucoronide
(M6G) were measured in the participants’ plasma samples
collected during the study by liquid chromatography-tandem
mass spectrometry. From each participant 10 blood samples
were collected pre and post-training (see Figure 1). Serum was
separated from the blood clot after centrifugation and stored at
−20◦C until analysis. Each sample was measured after enzymatic
cleavage using β-glucuronidase (Escherichia coli, 140 U/mg, 1 h
at 37◦C), and without enzymatic cleavage. After cleavage (1.5 ml
serum, 0.5 ng D3-morphine as internal standard, 2 ml phosphate
buffer pH 6, 50 µl β-glucuronidase) solid phase extraction (SPE)
was performed using mixed mode cation exchange cartridges
(CHROMABOND Drug, 200 mg, Macherey-Nagel, Düren,
Germany) on an automated SPE device (GX-274 ASPEC, Gilson,
Middleton, WI, USA). For the measurement without enzymatic
cleavage 2 ml serum was mixed with 2 ml of phosphoric acid
(4%) and internal standard (0.5 ng D3-morphine, D3-M3G,
and D3-M6G each). For SPE Oasis R© MCX cartridges (60 mg,
Waters, Milford, MA, USA) were used on a GX-274 ASPEC
(Gilson, Middleton, WI, USA). Chromatographic separation was
performed on a Shimadzu 1100 Series HPLC system equipped
with a Kinetex column (100 mm × 2.1 mm, 2.6 µm particle
size; Phenomenex, Aschaffenburg, Germany) applying gradient
elution. A QTrap 5000 triple quadrupole linear ion trap mass
spectrometer fitted with a TurbolonSpray interface (Applied
Biosystems/Sciex, Darmstadt, Germany) was used in MRM mode
(positive mode) for detection of the target compounds. Two
ion transitions were monitored per analyte and for quantitation
the peak area ratios of the target compound to the analogous
deuterated internal standard (D3-morphine, D3-morphine-3-
glucuronide, and D3-morphine-6-glucuronide) were used. Lower
limit of quantitation (LLOQ) was 2 pg/mL for morphine and
25 pg/mL for both morphine glucuronides. Calibration was linear
from 2 to 15 pg/mL for morphine and from 25 to 200 pg/mL for
the morphine glucuronides.
Attentional Network Performance
We measured the attention performance with the ANT (Fan et al.,
2002), which we also used as a control to see whether or not
the meditation training was effective. The ANT test assesses in
parallel three different components of the attentional network,
i.e., the alerting, the orienting, and the executive component. The
basic task of the ANT is a flanker task which is either facilitated
or impeded by the application of cues and distractors. The
dependent measure is reaction time (RT). Overall, six different
conditions are presented resulting from three cue conditions
(no cue, center cue, spatial cue) and two target conditions
(congruent and incongruent). Performance indicators for the
FIGURE 1 | Study flow. Day 1: a personal talk with each participant, scale
weight. Results held no entrance in the analysis and served only as a test run,
making the participants familiar (acquainted) with the setting. Day 2: results
served as the baseline. Days 3–7: mindfulness training/no intervention Day 8:
intervention group: 10 min meditation practice before experiment. Days 9 and
10: 10 min meditation practice for the intervention group. Naloxone or saline
administration. Naloxone or saline were administered via a venous port
following a blinded, randomized and controlled protocol.
three attentional components are obtained by computing several
RT differences between these six conditions. The ANT test
was performed on day 2 (baseline) and days 8–10 before the
tourniquet-test. The test consisted of six blocks (of 48 trials
with no feedback which were distributed over the assessment
days). About 3 min of practice procedure was held before the
experiment.
Self-Reported Mindfulness
Freiburg Mindfulness Inventory
The FMI (Buchheld et al., 2001; Walach et al., 2006) is a
short form with 14 items suitable also for participants without
profound background knowledge in mindfulness. It provides
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a reliable and consistent scale evaluating important aspects of
mindfulness. It is considered as one dimensional for practical
purposes. Items are scored on a four point Likert scale ranging
from 1 (strongly disagree) to 4 (strongly agree). Participants filled
in the questionnaire on day 2 (baseline) and days 8–10 before the
tourniquet-test.
Procedures
Possible participants for the study were pre-screened via phone
calls, following initial contact through postings, etc. If they
fulfilled inclusion criteria they were sent information documents
and a date for their assessment. During initial assessment,
eligibility was cross-checked and basic instructions provided.
For actual study enrolment, participants were distributed
among verum (intervention) and control group following a
standard randomization protocol. Upon successful enrolment,
each participant received an anonymized identification number
for further procedures. Enrolment stopped when calculated
sample sizes were met for both groups. Group assignment took
place by randomizing the whole sample (N = 32) at once into
two groups of equal size and was performed by a statistician who
was not involved in participant interaction. Group assignment
was noted in opaque and sealed envelopes with the identification
number on top of the envelope. Experimenters and study nurses
performing tourniquet tests, ANT tests and blood samples were
kept blind to the participants’ group assignment. Participants
were informed about their individual group assignment (to
get to know whether they would be required to show-up for
intervention training) after the completion of assessments on day
2 by a person otherwise not interacting with the participants.
Participants were told not to speak with other participants about
group assignment. For additional assignments – regarding the
sequence of hidden saline/naloxone administration on days 9 and
10 – both groups (N = 16, each) were randomized separately
again in one step in order to get four groups of the same size
(N = 8). Group assignment was again noted in sealed opaque
envelopes. Similarly to experimenters/study nurses, participants
were kept blind about these additional assignments. Naloxone
and NaCl infusions were prepared by two anesthesia nurses in
special laboratory in a different part of the building directly before
the application. The nurses opened the envelope and prepared the
infusions accordingly which were then handed over to the MDs.
The nurses had no direct interaction with the participants.
All participants were required, and instructed as such, to
strictly avoid poppy/poppy seed consumption during study
enrolment and the course of the study to avoid positive morphine
or morphine glucuronide findings caused by adhering alkaloid
residues (from external sources). Overall duration of the study
was 10 days, following an adjusted standard protocol (Amanzio
and Benedetti, 1999) (see also flow chart – Figure 1):
Day 1: A personal introduction was given to each participant,
explaining the procedures in-depth and discussing remaining
questions. Participants then gave informed consent and filled
in questionnaires (FMI, sociodemographics). After this, each
participant was weighed. Then the first run of the ANT and
pain tolerance test (tourniquet) was conducted. Results held no
entrance in the analysis and served only as a test run, making
the participants familiar with the setting.
Day 2: Attention Network Test, FMI, and tourniquet test were
measured. Results served as baseline.
Days 3–7: Depending on the group assignment, participants
were trained in the described meditation techniques (for
90 min) or had no task.
Day 8: Participants who were randomized in the intervention
group had their meditation practice (10” short group
meditation – breath awareness). ANT, FMI, and tourniquet test
were conducted for all participants thereafter.
Days 9 and 10: Meditation practice (10” short group
meditation – breath awareness) for the intervention group.
After that ANT, FMI and tourniquet test were conducted, this
time with either hidden naloxone or saline administration.
Sample Size, Data Analysis, and
Statistics
Sample size consideration was based on a power analysis with
an estimated effect size of d = 0.92 (α = 0.05, 1-β = 0.80) and
resulted in N = 32 (both groups). The power analysis was based
on the protocol and findings of Amanzio and Benedetti (1999).
Baseline measurements were compared by t-test for
independent measures or Chi2 test for differences. Hypothesis
A was assessed by an ANCOVA taking the baseline data as
covariates and this procedure was also applied to assess post-
intervention changes for the various indicators of the ANT as
well as for the FMI scores. Hypothesis B1 was tested by a repeated
measurement ANOVA for the naloxone and saline assessment
with baseline data (day 2) taken up as covariate. Here, we had
the factors group (between-subjects, intervention versus control)
and infusion (within-subject, naloxone versus saline). For this
hypothesis the group × infusion interaction was the relevant
indicator. Effect sizes were either partial η2 from the respective
analysis or Cohen’s d computed as the differences of the means
divided by the pooled standard deviation. Correlations were
computed with Spearman’s rho. All analyses were conducted by
SPSS 21.
RESULTS
Participants
Thirty-two participants were included and showed up on day 1.
One participant of the control group did not show up on days 8,
9, and 10 and had to be excluded. Groups are matching in age and
weight. Basic sample characteristics are depicted in Table 1.
Pain Tolerance
The main outcome was time to stand an ischemic pain stimulus
(tourniquet test, see Table 2). Pre-intervention baseline was
12 min 58 s for the intervention group and 13 min 18 s for
the control group. On the first post-intervention measurement
(day 8), intervention group gained 2 min 01 s (14 min 59 s,
d = 0.27), control group gained 5 min 37 s (18 min 53 s,
d = 0.54). The difference (Hypothesis A) was not significant
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(ANCOVA, F = 2.28, df = 1/28, p = 0.14, η2p = 0.075). The
pain test was repeated on days 9 and 10, immediately after
receiving either isotonic NaCl (saline) or naloxone via a venous
port. In the intervention group, pain tolerance under naloxone
remained technically unchanged (it was extended by 0 min 06 s,
to 13 min 04 s) and was extended by 1 min 04 s under saline
(placebo), compared to baseline. The control group showed an
extension of 3 min 00 s (16 min 18 s) for naloxone and 3 min
42 s (17 min 00 s) for placebo. Taken both groups together
participants could tolerate pain longer by 50 s under placebo
(15 min 28 s, SD = 6 min 32 s) than under naloxone (14 min
38 s, SD = 6 min 47 s); this difference was not significant
(t-test for dependent means, T = 1.46, df = 30, p = 0.16,
d = 0.13). There was no significant difference between groups
for the difference between naloxone and placebo (Hypothesis B1,
repeated measurement ANOVA F = 0.52, df = 1/28, p = 0.82,
η2p = 0.002).
Morphine
Mass spectrometric plasma analyses for morphine and morphine
glucuronides (M3G and M6G) revealed sporadic measures in
the pg/ml range (morphine: 2.8–221 pg/ml [LOQ: 2 pg/ml];
M3G: <25–417 pg/ml [LOQ: 25 pg/ml]; M6G: <25–35 pg/ml
[LOQ: 25 pg/ml]). Regarding correlations between morphine
detection and pain tolerance on intraindividual levels (i.e.,
within subject), our analyses revealed higher pain tolerance
with morphine co-occurring in seven out of nine cases (as
compared to series of pain measures in these subjects without
proof of morphine in the plasma). When morphine metabolites
(M3G, M6G) were additionally present in the plasma, that is,
coincidentally with morphine, six out of seven subjects showed
higher pain tolerance. Given the inability to confirm our initial
study objective (i.e., discrimination of pain tolerance between
groups due to mindfulness training/meditation intervention), we
abstained from more detailed elaboration on individual/sample
levels, or case studies on possible associations between individual
morphine values, naloxone effects, pain tolerances, and
mindfulness.
With no discernable patterns at general levels, and only
incidental opiate measures (36 positives in 310 samples, with
TABLE 1 | Sociodemographic data of the intervention and control group
(SD, standard deviation).
Intervention group Control group p
N 16 15
Mean age (SD) 27.8 (8.41) 25.5 (6.79) 0.42
Sex (m/f, absolute numbers) 5/11 3/13 0.41
Mean weight in kg (SD) 62.6 (12.70) 58.5 (11.43) 0.35
12 samples showing very low morphine concentrations only
with glucuronides not detected), we could only speculate
whether morphine values originated form external, alimentary
sources, or referred to its actual endogenous release. Possibly,
morphine bioavailability as well as first-pass effect (e.g.,
liver metabolism) would appear to make exogenous sources
less probable. However, we conducted additional experiments
involving mass spectrometric plasma analyses (not depicted
here), trying to describe and further narrow down ranges
for possible alimentary sources (e.g., accidental poppy seed
consumption). The results showed that morphine, M3G and
M6G concentrations reached in the study samples could be
explained by unintentional intake of poppy seed-containing food,
since even small amounts of poppy seeds, which may not be
noticed, e.g., in bakery products, can be sufficient to produce
positive blood morphine and morphine glucuronide findings in
the range of concentrations detected within the study population.
Taken together, despite instructing the participants to abstain
from consumption of poppy/poppy seeds, external sources for
morphine and metabolite detection in the study samples cannot
be ruled out completely. Results have thus to be dealt with
great care, which is why we refrained from further analysis and
interpretation.
Attention
Attention performance was tested with ANT: data for RT and
error scores were analyzed separately.
Reaction Time
Overall, participants improved significantly in RT at post-
intervention assessment (471 ms compared to 496 ms, T = 4.407,
df = 30, p < 0.001, d = 0.39). We computed ANCOVAS for the
three ANT indicators as well as for the overall RT and none of
these variables showed significant group differences (see Table 3).
Error Score
The error score describes the amount of errors participants
made (i.e., pressing the wrong button) while performing the
task. Since there is always a speed-accuracy trade-off, changes
are interesting with respect to the shorter RT found after the
intervention. Overall, participants made less error after the
intervention at the second assessment (2.76 compared to 2.65),
but this reduction was not significant (T = 0.374, df = 30,
p = 0.71). If analyzed for group differences, the groups showed
a tendency to perform different, with the meditators reducing
error after the intervention (see Table 4). If these error rates are
split up with respect to different RT as showed in the histogram
(Figure 2) one can see that meditators showed especially a better
performance in very short RTs. We compared the distribution of
TABLE 2 | Results of tourniquet test, mean time to stand ischemic pain in min:sec (SD) in the intervention group and control group.
Tourniquet test Day2 Baseline Day 8 Day 9 Day 10 Naloxon Placebo
Intervention group 12:58 (6:00) 14:59 (8:29) 13:13 (6:14) 13:53 (7:33) 13:04 (7:01) 14:02 (6:49)
Control group 13:18 (7:27) 18:53 (12:26) 16:50 (6:17) 16:29 (6:08) 16:18 (6:20) 17:00 (6:04)
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TABLE 3 | Attention Network Test (ANT) results for reaction time differences (ms). Differences between groups at post-test based on ANCOVA with
pre-test as covariate.
Intervention group Controls
Mean SD Mean SD F df p η2p
Overall Pre 499 76.7 493 81.8 0.141 1/28 0.71 0.005
Post 474 60.9 467 47.4
Alerting Pre 33.66 21.006 31.47 14.760 0.646 1/28 0.43 0.023
Post 40.45 20.832 34.07 16.195
Orienting Pre 53.10 17.644 46.77 20.778 3.033 1/28 0.09 0.098
Post 41.30 19.553 42.83 20.231
Executive Pre 70.75 25.637 76.02 47.104 0.007 1/28 0.93 0.000
Post 59.61 21.239 61.64 23.326
TABLE 4 | Attention Network Test results for error score.
Intervention group Controls
Mean SD Mean SD F df p η2p
Overall Pre 2.51 2.787 3.02 2.200 3.887 1/28 0.059 0.122
Post 1.98 1.750 3.35 2.601
FIGURE 2 | Histogram of error scores at post-intervention for different reaction time (RT) windows (15 bins, width 40 ms). Distribution analysis showed
significant differences between the two groups (z = 3.23, p = 0.001 – see text).
meditators and controls with the non-parametric Wilcoxon Test
and found a significant difference (z = 3.23, p= 0.001).
Self-Attributed Mindfulness (FMI)
We assessed self-attributed mindfulness at baseline and after
the intervention. Data are displayed in Table 5. Here, larger
values indicate a higher level of self-attributed mindfulness.
No differences were found between the groups at baseline
(T = 0.471, df = 29, p = 0.64) and after the intervention (see
Table 5).
Correlational Analyses
We correlated change scores of FMI and ANT (Alerting,
Orienting, Executive, Error Score) with improvement in pain
from day 2 to day 8 for the meditation group only. None of these
correlations turned out significant. However, there was a medium
size correlation between increase of self-attributed mindfulness
and increase in pain tolerance (Spearman’s ρ = 0.33, n.s.). In
the whole sample this correlation reached significance with 0.36
(p= 0.046).
DISCUSSION
With our study, we wanted to learn more about possible
mechanisms in pain regulation and the neurobiology behind
alleged pain-reducing effects of mindfulness meditation (i.e.,
short novices training). Therefore, we applied established
protocols for experimental pain, and meditation training, also
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TABLE 5 | Results of Freiburg Mindfulness Inventory.
Intervention group Controls
Mean SD Mean SD F df p η2p
FMI Pre 37.0 4.50 37.9 6.42 0.026 1/28 0.87 0.001
Post 37.9 2.98 38.3 6.32
Test-statistic for differences at post-intervention (ANCOVA) with pre intervention values taken as covariate.
considering an overlap in physiology between placebo and
meditation autoregulation.
Claiming rigorous methodology, our study involved partial
blinding of participants and examiners, as well as randomization
and controlling procedures. In addition, the topic of pain, its
reduction or increased tolerance, was carefully avoided during
meditation training to eliminate vectored expectations. We
used standard procedures for experimental pain stimulation
from other placebo models (established placebo experiments).
Our hypotheses were that meditation training would lead
to an increased experimental pain tolerance, naloxone could
inhibit this effect, and an increased pain tolerance would,
presumably, correlate with improved attention performance, and
mindfulness.
As described, we were unable to discern and yet confirm an
increase of pain tolerance exclusively for the intervention group
(i.e., meditation training).
An indicator that our meditation training had an influence
on the participants can be drawn from the results from the
ANT. While there was no change in the RT for the three ANT
indicators, meditators showed a significantly different error score
distribution (post-training). This result is in accordance with
other meditation studies, using the ANT (Tang et al., 2007; van
den Hurk et al., 2010; Jo et al., 2016), where the same pattern,
i.e., fewer errors in trials with short RT following meditation
training, was found: the ANT results showed a statistically
significant smaller error score, especially for fast RTs. This is
also consistent with earlier findings that showed improvements
in the efficient distribution of attentional resources among
competing stimuli for meditation trained subjects (Kerr et al.,
2011). We furthermore found a significant correlation between
changes in self-attributed mindfulness (FMI) and changes in
pain tolerance for the entire sample of both groups combined.
This correlation might be due to repeated testing, but if not it
would indicate that self-attributions regarding being present and
acceptant are somehow related with pain tolerance. Taken into
account the fact that FMI results, surprisingly, did not differ
between groups the presence of this correlation in both groups
is consistent.
Increases in pain tolerance that were, indeed, measurable
occurred in both groups. They were particularly dominant
in the control group, which would, counterintuitively, reject
our initial hypothesis. Again, this could represent an effect of
learning, i.e., getting used to the experimental procedures over
time, although still hypothetical. We are aware of one study
that explicitly covers the topic of habituation from repeated
representation of painful stimuli of fixed intensity by assessing
the effect of mindful attention on pain habituation (Ginzburg
et al., 2015). However, we were unable to identify additional
studies confirming such supposable development of tolerance
with repeated exposures to pain test stimuli. The incidental or
structural nature of our findings thus remains an open question
at this point.
Naloxone showed a trend to decrease pain tolerance in
both groups, but plasma analyses for morphine and morphine
compounds (metabolites) revealed only sporadic measures, with
no clear or discernable patterns at this level. Accordingly, a
possible impact, or significance, of opioidergic/morphinergic
signaling in meditation and pain physiology remains largely
unanswered at this point. Interestingly, two recent studies
found contradictory evidence in this regard: Zeidan et al.
(2016), conducted a study on meditation-based pain relief,
also using naloxone as a possible antidote. However, they
failed to reverse meditation-induced analgesia by this and
yet concluded pain-reducing effects not to be mediated by
endogenous opioids. In sharp contrast, Sharon et al. (2016)
found that mindfulness meditation-induced analgesia in their
trials was reversed by naloxone in an experimental pain
model also using the presentation of noxious temperature as
pain stimulus (Sharon used cold; Zeidan used heat). They
additionally described meditation effects matching placebo
physiology.
Neurobiological Speculations: Where to
Go from Here?
We won’t decide at this point which direction future evidence
will take. Certainly, optimum “dose” of meditation training
altering pain-related effects and its specific (or not) impact
on activation of underlying pathways (including placebo
physiology) has to be discussed. In addition there is the
question whether meditation during or directly before pain
application, or a short-term meditation training for novices
as in our case, can easily be compared to mid-term or even
long-term meditation practice regarding pain perception and
its processing. Maybe some of the experiments conducted
so far stressed more the cognitive appraisal of pain whereas
others mainly tested emotion-related pathways (cf. Esch,
2014).
If, however, mindfulness in relation to pain was independent
of placebo and related physiology in the brain, including
opioid signaling, we would have to discuss more thoroughly
the nature of pain reduction in its core sense, i.e., discerning
primary pain inhibition from its secondary modulation, or
distinguishing ascending, spinal or even peripheral processing
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of painful stimuli versus their descending, central or brain-
derived (top–down) adjunct pathways; this differentiation would
also include attention versus distraction models, or a distinction
between perceived pain intensity on the one hand and
perceived “bothersomeness” of pain on the other. Accordingly,
subjective acceptance of pain, e.g., learning to “live with it,”
would become a critical focus – as this is also part of the
philosophical background of mindfulness (Hayes et al., 2004).
Acceptance would thus be a psychological process by which
attention toward pain, under certain conditions (e.g., low fear
of pain, low catastrophizing, etc.), may even be beneficial.
Clearly, pain is not just pain, instead, essentially an individual,
subjective phenomenon – and an increased control of emotional
reactions to pain would involve cognitive but also meta-
cognitive pathways. Therefore, not only afferent pain signaling
pathways would have to be examined more accurately in light
of these speculations, but also secondary and tertiary responses
to it, and the latter could be inhibited, one might speculate,
through (experienced) meditation practice. In this scenario,
afferent pain could be mentally suppressed, i.e., its appraisal
and otherwise inhabited responses would be centrally altered
or turned down, and consequently, pain “tolerance” would
increase.
Following Williams (2010), failure to switch off emotion
is due to the activation of mental representations of the
present, past, and future that are created independently of
external contingencies. Mindfulness training can thus be seen
as one way to teach people to discriminate such “simulations”
from objects and contingencies as they actually are. In
addition, he argues, it might not only be the pain that is
of importance here, but attending to the affected region of
the body in an even-handed way: a problem in chronic pain
would not only be the pain itself, but the ‘turning away’
from, the averting of attention from regions that give rise
to painful sensations, either through deliberate distraction,
or by thinking about the pain conceptually rather than
experiencing the sensations directly. Some authors (cf. Craig,
2003) even regard pain itself an emotion, i.e., a distinct
sensation and a motivation, calling it a specific emotion that
reflects homeostatic behavioral drive, similar to temperature,
itch, hunger, and thirst. Hence, pain per se would not be
negative (or positive), yet a biological necessity for homeostasis,
and pain modulation would primarily be considered emotion
autoregulation. Farb et al. (2015) conclude that many of these
processes can be understood through an emerging predictive
coding model for mind-body integration. Their model, which
describes the tension between expected and felt body sensation,
parallels contemplative theories, and contemplative practices,
such as meditation, may actually help to attenuate said
interpretative biases. Given these speculations, one could possibly
discriminate pain reduction in future experimental models
incorporating meditation – or placebo – practices, with an
involvement and activation of mechanisms that enhance the
primary inhibition of pain, from pathways using an innate
potential to control emotions. In other words: we would
have to additionally look at individual pain-response-control
potentials.
Taken together, in our experiments we saw the tendency
that a brief mindfulness training resulted in a – relatively –
decreased pain tolerance rather than an increased one. We suggest
this could be due to the fact that mindfulness rather is a skill
than having a directed ‘effect’ per se (e.g., on pain), especially
when no direction of expected effects is implied (no specific
outcomes predetermined, by default) and as such communicated
to participants. We should keep in mind that mindfulness
is not a method developed specifically for pain treatment.
Moreover, this newly acquired skill of mindfulness could also
lead to a more ‘sensitive’ perception of pain, that is, higher
pain awareness over the course. Interestingly, a recent study by
Sprenger et al. (2012) found that distraction reduces pain and
that this effect is modulated by naloxone, pointing toward the fact
that opioid neurotransmission is involved in attention-related
pain perception. This effect might be opposite to (or: competing
with) other pathways and neuronal mechanisms, or techniques,
for pain modulation, such as meditation and mindfulness.
We might have unintentionally activated different pathways
for pain proceeding, that is, attention and awareness versus
distraction, with a possibly pain-reducing effect of mindfulness
being counteracted by a decrease of distraction (i.e., mindfulness
would then, according to Sprenger et al. (2012), potentially
antagonize a pain-reducing effect of distraction). Again, given the
piloting character of our study, we can only speculate about said
autoregulatory phenomena.
Additional Limitations
Besides the question whether or not the chosen paradigm of our
study was appropriate, we additionally discussed cultural effects
and socioeconomic or regional cofounders on pain modulation,
considering general – including structural – differences between
Germany and other countries; such differences might have
played a role here, since our study, to our knowledge, was the
first one testing experimental pain tolerance in relation to a
short mindfulness training in a German setting. One question,
for example, would be whether having pain, given a certain
health care and delivery system, is considered a signal to utilize
and enter the system (having access to comprehensive care
and coverage), versus a possible threat to individual function
and dependent work issues and income options. Implications
of pain might thus be quite different – related, also, to the
question of social fallback systems, or pain as a threat to
existential needs, including differences in (social) tolerability for
pain.
Another limitation of our study might be that, although
using standardized methodology and protocols, the ischemic
pain stimulus wasn’t suitable for this kind of experiment.
We tested pain stimulation via tourniquet method on
ourselves, and we experienced an increasing unpleasantness
and numbness rather than actual experience of ‘pain.’ Again,
this raises the question whether pain perception might be a
term susceptible to interpretation, implying social, but also
to individual differences, and variance. Hence, the tendency
of pain tolerance in our study to decrease – relatively –
under naloxone (as compared to saline), could still point
toward a more universal activation, or involvement, of
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opioidergic mechanisms in pain modulation. However, as
described, we didn’t perform further analyses on this matter.
Further research would thus be needed, and is strongly
encouraged.
Is Meditation a Placebo Intervention?
The main point for discussion, however, would be whether
pain reduction or an increase of experimental pain tolerance
through mindfulness meditation training, as it had been shown
in other studies, but not in ours, appears to be a ‘placebo’
(rather learned) phenomenon, or, in fact, demonstrates an
original (‘inherited’) potential of mindfulness per se. In other
words: we carefully refrained from using the term ‘pain’ during
the training, and also left it open to each participant going
through the pain measurements to link the perception of
pain – or its tolerance – to meditation. We thus tried to avoid
active induction of expectations in this direction: this portion
of a possible placebo response was purposefully prevented.
Since the other portion, the conditioning part (supposedly
involved here: elicited through the experimental procedures
themselves), was the same for all participants, due to the
study flow and the sequence of pain measurements, the only
distinction at this point would be the training itself. Linked
here is the discussion if meditation itself can be seen as a
‘medication’ (cf. Shapiro et al., 2006), say, whether meditation
automatically and implicitly has specific, directed effects toward
pain. Hence, meditation practice requires active involvement,
and the participant’s decision, or effort, to learn the technique.
This makes it almost the opposite of a typical medication, as
this would usually be taken passively. We stress again that
pain was not addressed in the meditation practice; neither
was it part of the training to use the learned skill in such a
way nor was its assumed connection made explicit during the
experiments.
In another recent study by Zeidan et al. (2015) on meditation-
based pain relief in comparison to placebo analgesia, a distinction
could be made between the different pathways employed, with
mindfulness meditation activating higher-order brain regions
(e.g., orbitofrontal, anterior insular and cingulate cortices)
and placebo analgesia deactivating sensory processing regions
(e.g., secondary somatosensory cortex). Again, mindfulness
meditation seems to correlate with the cognitive modulation
of inner experience (e.g., pain), whereas placebo analgesia may
primarily relate to the sensory regulation and inhibition of
painful stimuli. However, the same study also demonstrated
an activation of the dorsolateral prefrontal cortex in placebo
analgesia, and the question remains unanswered whether
mindfulness actually possesses an inherent pain-“specific”
potential. Observed effects could also be due to a conditioning
response and implications toward cognitive control of painful
experiences, thereby proving an involvement of “unspecific” but
now directed (conditioned) pathways for pain relief. In fact,
meditation and placebo may very well overlap in this regard,
and the existence of placebo analgesia (elicited via “analgesic”
skin cream in this case), as a distinct neural entity, may not
exclude the existence of a (“analgesic”) placebo-meditation-
pathway.
Future Study Designs
Clearly, further research seems to be necessary for a better
understanding. For example, in a future study differentiating
between non-intentional meditation training (as in our case)
and another group where such intention is explicitly part
of the training, we would suggest a three-armed study,
with a passive control and an active training group (non-
intentional), accompanied by a third active group that explicitly
teaches mindfulness for pain control (as a “means for better
tolerating pain”). In this latter group, participants would
learn – and thus expect – to better cope and withstand
pain, given the overall idea of acceptance, non-judging, and
observing (as it is part of mindfulness training), even when
facing a painful stimulus. With such a design, a possible
overlap, as well as differences, between meditation and placebo
outcomes, and physiology, could possibly be discerned more
thoroughly.
However, this is a rather new area, and one could certainly not
expect to understand the full picture of underlying mechanisms
in only a few studies. Additional attempts are necessary. Also,
long-term comparative cohort studies might be needed over the
course to investigate the full potential of meditation techniques
in relation to pain tolerability.
CONCLUSION
A 5-day meditation training (approximately 460 min of
mindfulness training/exposure) may not lead to increased pain
tolerance.
Our results raise further questions: what part of assumed
effects is related to expectation or conditioning? Which portion of
earlier reported pain modulation through meditation is specific
and actually meditation-related? Does meditation function as a
‘medication’? Should meditation be seen as a skill or potential,
rather than producing discernable and predictable (objective,
generally reproducible) outcomes?
We surmise that mindfulness may have the potential to
reduce pain, but may not do so ‘automatically,’ as long as
the use of this skill and expected outcomes are not trained
simultaneously. When it occurs, this might also indicate
intentionally expected or conditioned effects. Given a possible
overlap between placebo studies and recent meditation studies
on experimental pain, one could speculate a physiological
interference between meditation and placebo phenomena. To
better understand these questions, further studies are urgently
needed.
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